Hively Brad's Form 4 filing
Starling Oncology, Inc. (DFPH) · filed Jun 5, 2025
- Accession no.
- 0000935836-25-000416
- Filed
- Jun 5, 2025, 6:51 PM ET
- Trade date
- Jun 3, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 6 non-derivative transactions and 4 derivative transactions. Open-market sales total $5.67M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Hively BradCIK 0001891124 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 3, 2025 | Common Stock | MOption exerciseAcquired | +684,528 | $0.85 | +$581,848.8 | 1,396,561 | Direct | |
| Jun 3, 2025 | Common Stock | MOption exerciseAcquired | +105,320 | $0.481 | +$50,658.92 | 1,501,881 | Direct | |
| Jun 3, 2025 | Common Stock | MOption exerciseAcquired | +131,297 | $1.87 | +$245,525.39 | 1,633,178 | Direct | |
| Jun 3, 2025 | Common Stock | MOption exerciseAcquired | +946,460 | $0.85 | +$804,491 | 2,579,638 | Direct | |
| Jun 3, 2025 | Common Stock | SSaleDisposed | −1,867,605 | $2.87 | −$5,360,586.63 | 712,033 | Direct | |
| Jun 3, 2025 | Common Stock | SSaleDisposed | −108,532 | $2.87 | −$311,519.4 | 603,501 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 3, 2025 | Common Stock | MOption exerciseAcquired | +684,528 | $0.00 | $0 | 0 | Direct | |
| Jun 3, 2025 | Common Stock | MOption exerciseAcquired | +105,320 | $0.00 | $0 | 0 | Direct | |
| Jun 3, 2025 | Common Stock | MOption exerciseAcquired | +131,297 | $0.00 | $0 | 0 | Direct | |
| Jun 3, 2025 | Common Stock | MOption exerciseAcquired | +946,460 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.